Navigation Links
NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
Date:4/14/2009

H1N1 Virus-like Particle (VLP) Vaccine Candidate Based on the 1918 Spanish Influenza Strain Protected Mice and Ferrets Against the Spanish Flu and Highly Pathogenic H5N1 Bird Flu

ROCKVILLE, Md., April 14 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today reported preclinical study results showing that an investigational H1N1 virus-like particle (VLP) vaccine based on the 1918 Spanish influenza strain protected against both the Spanish flu and a highly pathogenic H5N1 avian influenza strain. The study, published in the March 25, 2009 online issue of the Journal of Virology, was conducted by scientists from the Centers for Disease Control and Prevention (CDC) in Atlanta, GA and Novavax under a Collaborative Research and Development Agreement.

Novavax scientists designed and produced a recombinant VLP vaccine candidate against the 1918 H1N1 influenza strain. This 1918 influenza strain was responsible for more than 50 million deaths worldwide during the great Spanish flu pandemic. Mice and ferrets were vaccinated with VLPs by one of two routes: either by standard intramuscular injection or by administering a small drop of the VLP vaccine in the nose (intranasal immunization). All of the 1918 VLP-immunized animals were protected when exposed to a lethal dose of the 1918 influenza virus, regardless of the route by which the vaccine was administered. Remarkably, animals immunized by the intranasal route were also protected against a lethal dose of a contemporary, highly pathogenic avian influenza subtype H5N1 virus strain, isolated from a fatal human case in 2004 (A/Vietnam/1203/2004 strain).

The H1N1 VLP vaccine candidate was made up of the hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins from 1918 Spanish influenza virus strains. These proteins, which were
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
2. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
3. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
4. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
5. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
6. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
7. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
8. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
9. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
10. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
11. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China ... the "Company"), a leading fully integrated plasma-based biopharmaceutical ... announced that its majority-owned subsidiary, Shandong Taibang Biological ... ("GMP") certification from the China Food and Drug ... production facility. As previously disclosed in the Company,s ...
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... The Center for Professional Innovation ... training across the life sciences industry, has partnered with ... to provide the organization's members with discounted classroom courses, ... the more than 350 sessions across 80 course titles. ... when registering for a public course at ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... present a company update at the Morgan Stanley Healthcare Conference in New ... , , Interested parties may access a live ... BioMarin website, www.BMRN.com . A replay of the ...
... , NEW BRUNSWICK, N.J., Sept. 8 ... SNT ) today announced that the Company will be presenting at ... held at the New York Palace Hotel from September 9th - ... will deliver the Company,s corporate presentation on Friday, September 11th, at ...
... CAMBRIDGE, Massachusetts, September 8 Shire plc,(LSE: SHP, ... company, is,committed to doing everything possible to assist Gaucher ... is pleased to be,able to provide velaglucerase alfa well ... wide. , In the U.S., ...
Cached Biology Technology:BioMarin to Present at the Morgan Stanley Healthcare Conference 2Senesco Technologies to Present at 11th Annual Rodman & Renshaw Healthcare Conference 2Update on velaglucerase alfa 2Update on velaglucerase alfa 3
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... of the American Medical Society ("Medical News & ... Associate Professor Sergei Adamovich, a biomedical engineer. Adamovich and ... and Eugene Tunik, PhD, PT, at the University of ... robotic and virtual reality-based video game therapies to help ...
... that the animal with the most genes--about 31,000--is the ... By comparison, humans have about 23,000 genes. Daphnia is ... The water flea,s genome is described in a ... the Daphnia Genomics Consortium, an international network of scientists ...
... provided the first conclusive evidence that cannabis use significantly hastens ... brain development with possible life-long consequences. The ... smoking cannabis is associated with an earlier onset of psychotic ... an international team including Dr Matthew Large, from the University ...
Cached Biology News:JAMA features NJIT biomedical engineer helping stroke patients 2JAMA features NJIT biomedical engineer helping stroke patients 3The most genes in an animal? Tiny crustacean holds the record 2The most genes in an animal? Tiny crustacean holds the record 3Cannabis linked to earlier onset of psychosis 2
Goat polyclonal to NIR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SWARGPPKFESVP, corresponding to C terminal amino acids 962-974 of NIR1. Entrez Gene ID: 83394 ...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Biology Products: